FDA considers interim access for compounded peptides; Enspryng's label expansion
Plus news about Microbiotica, Cyrano Therapeutics and Opus Genetics. HHS and FDA submit peptide policy for review: An “interim access policy for compounding using certain peptides” is awaiting regulatory review at the White House Office ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.